human apotransferrin

Phase 2Biologic

PProthya Biosolutions

human apotransferrin is one of 37 biologic programs targeting Thalassemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThalassemiaActive, not recruiting

ThalassemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

84 competitors in Thalassemia

#DrugCompanyPhaseTrials

Legalon

BBukwang Pharmaceutical

Phase 3

1 2

Winrevair

Merck & Co.

Phase 2

1 3

Neoral

Novartis

Phase 2

1 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2

1 5

Jakafi

Incyte

Phase 2

1 6

Dacogen

Sun Pharma

Phase 2

2 7

Droxia

TTheravia

Phase 2

2 8

Endari

EEmmaus Medical, Inc.

Phase 2

2 9

CTX001

Vertex Pharmaceuticals

Phase 3

1 10

Campath

GGenzyme, a Sanofi Company

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Study completion

NCT01797055

Clinical

Trials by Indication[1]

Thalassemia1 trial

Apotransferrin in Patients With β-thalassemia

Terminated·PProthya Biosolutions·Phase 2·NCT03993613·10 enrolled

Haemophilia B1 trial

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

Completed·PProthya Biosolutions·Phase 4·NCT00139828·12 enrolled

Unspecified1 trial

Apotransferrin in Atransferrinemia

Active, not recruiting·PProthya Biosolutions·Phase 2·NCT01797055·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for human apotransferrin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — human apotransferrin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for human apotransferrin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Prothya Biosolutions company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: PProthya Biosolutions

human apotransferrin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Thalassemia1 trial

Haemophilia B1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News